Opill OTC has significantly increased contraceptive use and shifts from less effective options among women who are uninsured, of racial/ethnic minorities, and live in the rural US.
In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.